MX354493B - Derivados de los factores de coagulacion sanguinea vii y viia, conjugados y complejos que comprenden los mismos, y uso de los mismos. - Google Patents

Derivados de los factores de coagulacion sanguinea vii y viia, conjugados y complejos que comprenden los mismos, y uso de los mismos.

Info

Publication number
MX354493B
MX354493B MX2014004099A MX2014004099A MX354493B MX 354493 B MX354493 B MX 354493B MX 2014004099 A MX2014004099 A MX 2014004099A MX 2014004099 A MX2014004099 A MX 2014004099A MX 354493 B MX354493 B MX 354493B
Authority
MX
Mexico
Prior art keywords
facviia
facvii
derivative
blood coagulation
conjugate
Prior art date
Application number
MX2014004099A
Other languages
English (en)
Other versions
MX2014004099A (es
Inventor
Dae Jin Kim
Se Chang Kwon
Sung Youb Jung
Byung Sun Lee
Sung Hwan Hong
Yong Ho Huh
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of MX2014004099A publication Critical patent/MX2014004099A/es
Publication of MX354493B publication Critical patent/MX354493B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un derivado del factor de coagulación sanguínea VII, un derivado del factor de coagulación sanguínea Vila, conjugados de FacVll y FacVlla preparados cada uno enlazando un polímero que puede extender la semivida en sangre al derivado, complejos de FacVll y Vila preparados cada uno enlazando un vehículo al conjugado, genes que codifican los derivados de FacVll y FacVIIa, vectores de expresión que comprenden los genes, transformantes introducidos con los vectores de expresión, un procedimiento para preparar los derivados de FacVll y FacVlla usando los transformantes, un procedimiento para preparar el conjugado y complejo de FacVlla, un complejo de FacVlla preparado por el procedimiento, una composición farmacéutica para la prevención o el tratamiento de la hemofilia que comprende el derivado, el conjugado o el complejo como principio activo, y una composición farmacéutica para la coagulación sanguínea que comprende el derivado, el conjugado o el complejo como principio activo. Además, la presente invención se refiere a un procedimiento para prevenir o tratar la hemofilia o para promover la coagulación sanguínea, que comprende administrar a un sujeto una cantidad terapéuticamente eficaz de la composición. El derivado de FacVll o FacVlla de la presente invención se puede unir con un vehículo que puede mejorar la semivida en sangre mientras mantiene la actividad de FacVll o FacVlla, y se pueden usar ampliamente en el desarrollo de un agente profiláctico o terapéutico eficaz para la hemofilia.
MX2014004099A 2011-10-06 2012-10-05 Derivados de los factores de coagulacion sanguinea vii y viia, conjugados y complejos que comprenden los mismos, y uso de los mismos. MX354493B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110102099 2011-10-06
PCT/KR2012/008102 WO2013051900A2 (en) 2011-10-06 2012-10-05 Blood coagulation factor ⅶ and ⅶa derivatives, conjugates and complexes comprising the same, and use thereof

Publications (2)

Publication Number Publication Date
MX2014004099A MX2014004099A (es) 2014-05-21
MX354493B true MX354493B (es) 2018-03-08

Family

ID=48044320

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004099A MX354493B (es) 2011-10-06 2012-10-05 Derivados de los factores de coagulacion sanguinea vii y viia, conjugados y complejos que comprenden los mismos, y uso de los mismos.

Country Status (17)

Country Link
US (1) US9597378B2 (es)
EP (2) EP2763693A4 (es)
JP (1) JP6108630B2 (es)
KR (1) KR20130037659A (es)
CN (1) CN103974716B (es)
AR (1) AR088267A1 (es)
AU (1) AU2012319308B2 (es)
BR (1) BR112014008224A2 (es)
CA (1) CA2851223A1 (es)
IL (1) IL231930A0 (es)
MX (1) MX354493B (es)
MY (1) MY168754A (es)
RU (1) RU2620072C2 (es)
SG (1) SG11201401205UA (es)
TW (1) TWI565715B (es)
WO (1) WO2013051900A2 (es)
ZA (1) ZA201402745B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
TWI641382B (zh) * 2013-01-31 2018-11-21 韓美藥品股份有限公司 於包含因子ｖｉｉ之組成物中使病毒失活之方法
CN103397009B (zh) * 2013-08-16 2015-06-03 安源生物科技(上海)有限公司 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途
CN103599527A (zh) * 2013-08-16 2014-02-26 安源生物科技(上海)有限公司 包含改良型人凝血因子FVII-Fc融合蛋白的药物组合物
KR20150026024A (ko) * 2013-08-30 2015-03-11 한미약품 주식회사 인간 혈액응고 7인자 유도체의 대량 생산 방법
CA2944138C (en) * 2014-03-31 2023-06-20 Hanmi Pharm. Co., Ltd. Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
US11078336B2 (en) 2015-11-10 2021-08-03 Sun Chemical Corporation Alkoxylated dispersing agents
KR102041671B1 (ko) * 2017-05-08 2019-11-28 가톨릭대학교 산학협력단 β-아밀로이드 단백질의 응집을 억제하는 생체친화적 펩타이드
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
WO2019240881A2 (en) * 2018-04-23 2019-12-19 Emory University Vip and vip agonists, nanoparticles, and uses in inflammatory t-cell mediated disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058935A2 (en) * 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
US7235638B2 (en) * 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
BR0208203A (pt) * 2001-03-22 2005-04-19 Novo Nordisk Healthcare Ag Polipeptìdeo do fator vii, derivado do fator vii, composição, composição farmacêutica, construção de polinucleotìdeo, célula hospedeira eucariótica, animal transgênico, planta transgênica, e, métodos para produzir o polipeptìdeo do fator vii e um derivado do fator vii, uso de um derivado do fator vii, métodos para o tratamento de episódios de hemorragia ou distúrbios de hemorragia em um paciente ou para a intensificação do sistema hemostático normal e para inibir a formação de trobo em um paciente
AU2003242507A1 (en) * 2002-07-12 2004-02-02 Novo Nordisk A/S A tissue factor binding immunoconjugate comprising factor viia
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP1673453A2 (en) * 2003-10-07 2006-06-28 Novo Nordisk Health Care AG Hybrid molecules having factor vii/viia activity
JP4870569B2 (ja) * 2003-11-13 2012-02-08 ハンミ ホールディングス カンパニー リミテッド 免疫グロブリン断片を用いた蛋白質結合体およびその製造方法
WO2006134174A2 (en) * 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Dimeric and multimeric fviia compound
US8476234B2 (en) 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2007144173A1 (en) 2006-06-14 2007-12-21 Csl Behring Gmbh Proteolytically cleavable fusion protein comprising a blood coagulation factor
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
KR100880509B1 (ko) 2006-10-16 2009-01-28 한미약품 주식회사 재조합 단백질의 대량 생산을 위한 신규한 벡터, 발현세포주 및 이를 이용한 재조합 단백질의 생산 방법
KR101104684B1 (ko) 2008-12-02 2012-01-16 이화여자대학교 산학협력단 관찰 방향 및 조명을 고려한 피부 질감 렌더링 방법 및 그 장치
EP2387413A4 (en) * 2009-01-19 2015-12-23 Bayer Healthcare Llc PROTEIN CONJUGATE WITH AN ENDOPEPTIDASE-SPLICABLE BIOPROTEKTIVES PART

Also Published As

Publication number Publication date
TWI565715B (zh) 2017-01-11
CA2851223A1 (en) 2013-04-11
AU2012319308B2 (en) 2017-08-31
RU2620072C2 (ru) 2017-05-22
IL231930A0 (en) 2014-05-28
NZ623726A (en) 2016-06-24
EP3417881A1 (en) 2018-12-26
KR20130037659A (ko) 2013-04-16
RU2014115291A (ru) 2015-11-20
SG11201401205UA (en) 2014-05-29
BR112014008224A2 (pt) 2017-04-11
ZA201402745B (en) 2016-04-27
CN103974716B (zh) 2016-08-24
EP2763693A2 (en) 2014-08-13
CN103974716A (zh) 2014-08-06
WO2013051900A2 (en) 2013-04-11
US20140271607A1 (en) 2014-09-18
WO2013051900A3 (en) 2013-06-13
MY168754A (en) 2018-11-30
MX2014004099A (es) 2014-05-21
AU2012319308A1 (en) 2014-05-01
JP2014530018A (ja) 2014-11-17
TW201331223A (zh) 2013-08-01
US9597378B2 (en) 2017-03-21
JP6108630B2 (ja) 2017-04-05
EP2763693A4 (en) 2015-12-09
AR088267A1 (es) 2014-05-21

Similar Documents

Publication Publication Date Title
MX354493B (es) Derivados de los factores de coagulacion sanguinea vii y viia, conjugados y complejos que comprenden los mismos, y uso de los mismos.
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
MX2014002555A (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
MY164730A (en) Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
NZ604029A (en) Methods of treating bladder cancer
NZ621433A (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
WO2011130753A3 (en) Functionalized nano- and micro-materials for medical therapies
WO2009128918A8 (en) Combination therapy using a soluble hyaluronidase and a bisphosphonate
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX353964B (es) Agentes terapeuticos y usos de los mismos.
SG179027A1 (en) Dosage regimen for administering an epcamxcd3 bispecific antibody
MX358680B (es) Usos de inmunoconjugados dirigidos a cd138.
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
RU2015102772A (ru) Бензодиазелипы для мелкоклеточного рака легкого
WO2014160216A3 (en) Dual targeting anticancer agents
MX2011011058A (es) Antagonistas del receptor ep4 para el tratamiento de cancer.
NZ601559A (en) Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
EA201590191A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и фампридина
MX2015016750A (es) Composicion inmunogenica para uso en terapia.
MX2015007402A (es) Fusion de hormona de crecimiento humano y albumina, formulacion y usos de los mismos.
BRPI0508982A (pt) uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11
RU2013108390A (ru) Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека
BRPI0508983A (pt) uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluido um sal de maleato de azd2171 e um taxano, composição farmacêutica, kit, e, método para a produção de efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano

Legal Events

Date Code Title Description
FG Grant or registration